Protagonist Therapeutics, Inc.
PTGX
$56.25
$0.040.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -80.42% | -83.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -80.42% | -83.40% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -80.42% | -83.40% | |||
| SG&A Expenses | -10.11% | 31.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.09% | 8.60% | |||
| Operating Income | -117.72% | -115.23% | |||
| Income Before Tax | -196.86% | -108.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -198.34% | -108.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -198.34% | -108.85% | |||
| EBIT | -117.72% | -115.23% | |||
| EBITDA | -118.85% | -115.03% | |||
| EPS Basic | -195.79% | -108.76% | |||
| Normalized Basic EPS | -194.30% | -108.63% | |||
| EPS Diluted | -189.47% | -109.57% | |||
| Normalized Diluted EPS | -194.30% | -109.20% | |||
| Average Basic Shares Outstanding | 0.87% | 1.02% | |||
| Average Diluted Shares Outstanding | 0.87% | -5.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||